Tumor-Infiltrating PD-1^hiCD8⁺-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers.

Interestingly, the signature scores were significantly higher in responders than in nonresponders, except in one cohort where the difference was nearly significant ( p =0.096) ( Figures 3A–H ).

also in 3,287 other papers